Farnesyl Diphosphate Synthase Promotes Proliferation of Hepatocellular Carcinoma Cells by Interacting With Glucose‐6‐Phosphate Dehydrogenase
Cancer Medicine · 2026-02 · 15 (2)
DOI: 10.1002/cam4.71620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 10.02.2026. Verfasst von Jingfeng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Immunity and Inflammatory Diseases, Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Geranyltranstransferase, Glucosephosphate Dehydrogenase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Innovation Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is a highly aggressive malignancy characterized by metabolic reprogramming that supports tumour growth and survival. This study identifies farnesyl diphosphate synthase (FDPs), a key enzyme in the mevalonate pathway, as a critical regulator of HCC proliferation and apoptosis.
Methods
We applied bioinformatics analysis through TCGA and GSE database to identify the expression of FDPs within HCC patients. Then, mechanistic studies were conducted including Western blots, apoptosis assay, RT‐qPCR, rescue assay, RNA‐sequencing, in vivo study to prove the role of FDPs in regulating HCC progression.
Results
FDPs was found to be significantly upregulated in HCC tissues, and its down‐regulation promotes tumour cell apoptosis while inhibiting tumour cell proliferation in vitro and in vivo. Mechanistically, we identified FDPs regulate glucose‐6‐phosphate dehydrogenase (G6PD) by RNA sequencing, bioinformatics prediction, and rescue experiments, indicating its involvement in glycolysis regulation in tumour cells. The identification of this FDPs–G6PD axis suggests a novel metabolic pathway contributing to HCC development.
Conclusion
In summary, this study highlights FDPs play an essential oncogenic role in HCC, linking it to metabolic reprogramming and tumour survival. These findings establish FDPs as a promising therapeutic target, offering a foundation for further exploration of its regulatory mechanisms and potential clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Key Laboratory of Immunity and Inflammatory Diseases, Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, China.
- Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen, China.
- Department of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen, China.
ORCID-Profile: Jingfeng Liu
Förderung
- Shenzhen Science and Technology Innovation Program
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Zhu, Y., Lv, J., Hu, X., & Zhong, Y. (2026). Farnesyl Diphosphate Synthase Promotes Proliferation of Hepatocellular Carcinoma Cells by Interacting With Glucose‐6‐Phosphate Dehydrogenase. Cancer Medicine, 15(2). https://doi.org/10.1002/cam4.71620
Vancouver
Liu J, Zhu Y, Lv J, Hu X, Zhong Y. Farnesyl Diphosphate Synthase Promotes Proliferation of Hepatocellular Carcinoma Cells by Interacting With Glucose‐6‐Phosphate Dehydrogenase. Cancer Medicine. 2026;15(2). doi:10.1002/cam4.71620
BibTeX
@article{Liu2026,
author = {Liu, Jingfeng and Zhu, Yisheng and Lv, Jiyang and Hu, Xiaohao and Zhong, Yan},
title = {Farnesyl Diphosphate Synthase Promotes Proliferation of Hepatocellular Carcinoma Cells by Interacting With Glucose‐6‐Phosphate Dehydrogenase},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {2},
doi = {10.1002/cam4.71620}
}
EUVIMED